Clinical Trials in Colorado

Showing 4181-4200 of 18,143 trials

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05913232

The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.

Glaucoma Open-Angle PrimaryOcular Hypertension

D. Western Therapeutics Institute, Inc.201 participantsStarted Aug 2023

Glendale, California, United States • Colorado Springs, Colorado, United States • Lakeland, Florida, United States +6 more locations

Active Not RecruitingPhase 341 miles

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681

This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria. 2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)

Chronic Lymphocytic Leukemia

Acerta Pharma BV535 participantsStarted Jun 2015

Goodyear, Arizona, United States • Phoenix, Arizona, United States • Anaheim, California, United States +152 more locations

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Find Trials by Condition in Colorado

Using CTA Measures to Define Cardiac Risk In NFL Alumni

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus

Clinical and Basic Investigations Into Congenital Disorders of Glycosylation

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

Study of Uterine Prolapse Procedures - Randomized Trial

Beating Heart Mitral Valve Repair With the HARPOON™ System

Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

Improving Mobility After Revascularization in Peripheral Artery Disease

Resiliency in U.S. Air Force Personnel

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology Lens

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Effects of 5HTP on the Injured Human Spinal Cord